Telix Pharmaceuticals Limited (TLX) – What Are Brokerages Thinking About This Stock?

Telix Pharmaceuticals Limited (NASDAQ:TLX) has been given a consensus recommendation of “Moderate Buy” by the five analysts that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $20.50.

TLX has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Wednesday, October 21st. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a research report on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, August 21st. Royal Bank Of Canada raised Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Telix Pharmaceuticals in a research report on Friday, September 25th.

Institutional Investors Weigh In On Telix Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its position in Telix Pharmaceuticals by 523.8% in the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after acquiring an additional 8,423 shares during the period. XY Capital Ltd bought a new stake in Telix Pharmaceuticals during the first quarter worth about $120,000. WoodTrust Financial Corp bought a new stake in Telix Pharmaceuticals during the third quarter worth about $186,000. Private Advisor Group LLC increased its holdings in shares of Telix Pharmaceuticals by 276.3% during the first quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after buying an additional 128,070 shares in the last quarter. Finally, Hennion & Walsh Asset Management Inc. acquired a new stake in shares of Telix Pharmaceuticals during the second quarter worth approximately $1,731,000.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ:TLX opened at $9.51 on Friday. The stock has a fifty day moving average of $11.12 and a 200-day moving average of $9.86. The company has a current ratio of 2.01, a quick ratio of 1.85 and a debt-to-equity ratio of 1.16. Telix Pharmaceuticals has a one year low of $6.28 and a one year high of $13.11.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its programs are designed to support precision medicine by using radioactive compounds to image specific biological targets or deliver radiation directly to diseased tissue.

The company’s principal commercial product is Illuccix, a kit used to prepare gallium Ga 68 gozetotide injection for prostate-specific membrane antigen (PSMA) positron emission tomography (PET) imaging.